Cannabis Suisse Corp
15.7.2021 14:02:27 CEST | ACCESS Newswire | Press release
DIETIKON, SWITZERLAND / ACCESSWIRE / July 15, 2021 / Cannabis Suisse Corp. (OTC PINK:CSUI), a Nevada incorporated distribution company for recreational cannabis products and CBD oils, announces the results of laboratory testing of its new product line created for the upcoming launch on Shopify.
This news follows a recent announcement on the decision to choose ACS Laboratory as a CBD laboratory for testing the first shipment of the new Swiss4Life CBD brand, created for the launch of an online store on Shopify platform. The samples of products were sent to ACS laboratory to obtain СOA proving the quality of the new brand name CBD oils to the potential customers.
The certificates are ready for all the six types of current products: THC Free CBD Oil (Cherry Vanilla and Creme de Menthe) and CBD Tinctures with different therapeutic effects.
THC Free CBD Oil 1500 mg Cherry Vanilla has 1,521.586mg of Cannabinoids total (5.376%). 5.096% (1,442.211mg) are represented by CBD, 0.131% (36.992mg) are CBG, 0.051% (14.474mg) are CBN. The number of other Cannabinoids is 0.099% (27.909mg). THC is not detected.
THC Free CBD Oil 2500 mg Creme de Menthe contains 2,458.295mg of Cannabinoids total (8.654%). 8.177% (2,322.842mg) are represented by CBD, 0.209% (59.457mg) are CBG, 0.098% (27.851mg) are CBN. The number of other Cannabinoids is 0.169% (48.145mg). THC is not detected.
THC Free CBD Oil 3500 mg Cherry Vanilla has 3,513.119mg of Cannabinoids total (12.299%). 11.770% (3,362.096mg) are represented by CBD, 0.275% (78.554mg) are CBG, 0.115% (32.821mg) are CBN. The number of other Cannabinoids is 0.139% (39.648mg). THC is not detected.
CBD TINCTURES Anti-Inflammatory/Pain Relief/Focus contains 934.326mg of Cannabinoids total (3.328%). 3.314% (930.404mg) are represented by CBD, THC is not detected.
CBD TINCTURES Anti-Inflammatory/Pain Relief/Anti-Stress Formula has 920.788mg of Cannabinoids total (3.652%). 3.632% (915.728mg) are represented by CBD, THC is not detected.
CBD TINCTURES Natural Sleep Formula contains 913.149mg of Cannabinoids total (3.331%). 3.331% (913.149mg) are represented by CBD, other Cannabinoids or THC are not detected.
Since the Company received the certificates of analysis, a special page has been created on the site in the "LEARN" section so that users can see them at any time on their own and make sure of their authenticity. The COA were uploaded there along with the testing date.
ABOUT CANNABIS SUISSE CORP.
Cannabis Suisse Corp. is a public US Company incorporated in Nevada state. The Company operates in the field of distribution of recreational cannabis products and CBD oils. Cannabis Suisse Corp. currently sells via a distribution network of retailers and online shops, under the retail brand Swiss4Life. Swiss4Life products are made of USA hemp only and contain no THC, GMO or Gluten. They have not been evaluated by the FDA and are not designated for medical use. However, all the products available are manufactured by FDA Registered Entities and tested by independent third-party laboratories. Cannabis Suisse Corp's products are laboratory tested to ensure the end-users have access to a standardized, safe, and consistent product.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that
are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.
CONTACT:
Alain Parrik
Cannabis Suisse Corp.
+41445865314
alain.parrik@cannabissuisse.biz
SOURCE: Cannabis Suisse Corp.
View source version on accesswire.com:
https://www.accesswire.com/655563/Cannabis-Suisse-Corp-Announces-the-Results-of-Laboratory-Testing-of-Its-New-Product-Line-and-Creation-the-LEARN-Section-on-the-Website
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Review of 31 Studies Finds Vegan Dog Food and Vegan Cat Food Are Well Digested30.7.2026 21:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 30, 2026 / A new scientific review has found that nutritionally sound vegan dog food, vegan cat food and vegetarian pet diets are generally well digested and broadly comparable to conventional meat-based diets. The review, published in the journal Animals, examined 31 existing studies assessing the digestibility of vegan, vegetarian and plant-based pet diets and ingredients in dogs and cats. Twenty-two studies focused on dogs, two on cats and seven included both species. The review found that across a wide range of study designs, dietary ingredients and digestibility measures, vegan and vegetarian diets consistently showed high digestibility and were not normally significantly less digestible than conventional meat-based diets. Digestibility is an important factor because it indicates how effectively animals can absorb and utilise nutrients from food. While modern commercial plant-based pet foods are generally formulated to provide all essential nutr
Polaris Renewable Energy Announces Q2 2026 Results30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS Second quarter consolidated energy production totaled 199,130 MWh, representing a 8% decrease from 215,797 MWh in the same quarter last year. The decrease was consistent with management's expectations and primarily reflects higher curtailment in the Dominican Republic and the return to normalized hydrological conditions in Peru and Ecuador. The comparative period benefited from exceptionally strong
Polaris Renewable Energy Declares Quarterly Dividend30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on August 21st, 2026, to shareholders of record at the close of business on August 10th, 2026. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compa
New GTDC Research Illuminates Distribution's Expanding Role in Modern Technology Ecosystems29.7.2026 15:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / July 29, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, today released a new research report, The Evolving Role of Distribution in Technology Go-To-Market Models, developed in partnership with Channelnomics. The study examines the shift in distribution from a traditional channel intermediary into a strategic operating platform that helps vendors and partners scale, increase support and overcome the complexities associated with innovation (i.e., AI and cybersecurity) and integration. According to the research, customer expectations are rising rapidly as organizations seek integrated outcomes across AI, cybersecurity, hybrid cloud, automation, analytics and managed services. Vendors and partners increasingly struggle to meet those market demands independently with solutions requiring cross-platform integration, multi-vendor coordination, lifecycle support and operational consistency. The G
TIS, EuroFinance Study Finds Corporate Treasurers Actively Evaluating AI, But Hesitant to Adopt It28.7.2026 15:00:00 CEST | Press release
The EuroFinance Deep Dive, supported by Treasury Intelligence Solutions (TIS), interviewed and surveyed corporate treasury leaders, finding that while they see AI as a powerful tool for cash forecasting, multiple concerns are deterring them from adopting it - for now. BERLIN, DE / ACCESS Newswire / July 28, 2026 / Treasury Intelligence Solutions (TIS), a best-in-class solution for payments and cash management, partnered with the research and trade association EuroFinance, in a research initiative that discovered nearly half of leading corporate finance teams are considering the use of artificial intelligence in cash forecasting - but just as many are holding off because of concerns over the technology. The EuroFinance Deep Dive, AI in Treasury: Accuracy, Intelligence and the Future of Cash Forecasting, brings together proprietary research, survey data, and perspectives from treasury leaders at Microsoft, Siemens Energy and other companies to assess where AI is creating value and where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom